Vaccine Packaging Market By Packaging Type (Vials, Ampoules, Prefilled Syringes, Cartridges, Bottles, Others), By Vaccine Type (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, mRNA Vaccines, Viral Vector Vaccines, DNA Vaccines, Others), By Material (Glass, Plastics, Rubber, Aluminum Foil, Paper & Paperboard, Others), By Usage (Single-Dose Packaging, Multi-Dose Packaging), By Distribution Channel (Direct Sales, Distributors, Online Channels, Retail Pharmacies), and By End User (Hospitals & Clinics, Vaccination Centers, Pharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Government Agencies, Research Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Industry Outlook

The Vaccine Packaging market accounted for USD 1.83 Billion in 2024 and USD 1.95 Billion in 2025 is expected to reach USD 3.74 Billion by 2035, growing at a CAGR of around 6.72% between 2025 and 2035. Key drivers include expanding global immunization programs, improved cold chain infrastructure, and rising demand for safe, convenient single-dose vaccines. Vaccine packaging market denotes the industry that deals with creating customised packaging of vaccines at production and provision. This packing guarantees the vaccine's storage and transportation to distribution in a safe manner without losing efficacy and stability. It consists of vials, ampoules, syringes, cold chain packaging, and labelling material that prevent contamination of vaccines, temperature fluctuations, and physical damage. As the world is being vaccinated at an increasing rate and safe immunisation seems to be the key to controlling the spread of the pandemic, the market is expanding extremely fast due to the technological breakthroughs and high standards of regulations.

Industry Experts Opinion

"SCHOTT’s borosilicate glass packaging, including vials intended for COVID‑19 vaccines and therapies, are proven to minimize drug and container interactions … Without these remarkable containers … there is no way the world could safely distribute a vaccine within the timelines that this moment in history demands."

• Mark Gilvey, Plant Manager at SCHOTT Lebanon, PA

"Packaging vaccines using prefilled syringes can increase dosing efficiency, reduce costs, and improve patient safety."

• Philip Song, Senior Editor at BioPharm International

Report Scope:

Market Dynamics

Rising global immunization programs are supported by public health initiatives.

Immunisation programmes are needed globally, so this is the heart of the vaccine packaging market, which is fuelled by government and other health agendas worldwide. Immunisation campaigns to curb the spread of infectious diseases are being pursued actively by governments and international organisations such as the World Health Organisation (WHO), and this induces a demand for safe and effective packaging of vaccines since much of the success of the vaccination process relies on the fact that safe and effective packaging is completed. UNICEF estimates that in 2022, more than 116 million children were immunised around the world, showing high levels of advocacy toward vaccination.

The Centers for Disease Control and Prevention (CDC) has emphasised the importance of packaging in ensuring that the cold chain is maintained, which is important in the stability of the vaccine, particularly in the case of sensitive vaccines such as the mRNA COVID-19 jabs. The enhanced awareness of the population about vaccine-preventable diseases and the investments of the public health organisations in healthcare infrastructure stimulate the need for new advanced and trusted packaging.

The increase in the number of immunisation programmes in developing nations, which is aided by programmes like Gavi, the Vaccine Alliance, is also a contributor to market development. The advanced forms of packaging materials and technologies are hastened by the interest in how vaccine wastage is improved and patient safety, as piloted by governments and health bodies, which are keen on enhancing the vaccine coverage globally.

The growing demand for single-dose vaccines ensuring safety and convenience.

The rapidly increasing demand for single-dose vaccines is one of the major stimulating factors in the vaccine packaging market because of the necessity of increasing safety, convenience, and better coverage of the immunisation rates. Single-dose vaccines eliminate the threat of contamination and errors in measuring the dosage, more so than multi-dose vials, which is essential in sustaining the efficacy of the vaccinations and the safety of the patient. Moreover, they are easier to handle and manage, especially in low-resource or distant areas, which aids in public health management. CDC stated that single-dose vaccines have increased the immunisation rates due to easier logistical planning and decreased wastage.

According to the World Health Organisation (WHO), single-dose packaging facilitates the management of the cold chain since it reduces the threat of spoilage of vaccines, manifested in transportation and storage. All these comprise factors that push initiatives in vaccine packaging design, focusing on safe and convenient modes that satisfy regulatory norms and the health needs of the greater community. Due to the growing demand and priorities on vaccination implementations globally or the pandemic preparedness, a particular increase in the demand for single-dose vaccine packaging will take place. Through government initiatives through immunisation programmes, manufacturers are prompted to pursue sophisticated packaging technologies such that the integrity of the vaccines is maintained and shelf life increased. The transition improves patient outcomes and helps to sustain the healthcare practice by decreasing the waste package usage.

Regulatory complexities delay product approval and international distribution.

The vaccine packaging market is restrained by the lack of imagination in advertising and regulatory complexity that prevents timely product approval and international release. Lucrative packaging testing and validation procedures are established by regulatory authorities like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) with the aim of testing and validating the packaging to meet the safety and efficacy requirements, and the required cold chain requirements. Such processes tend to delay development periods, thus making it difficult to enter the market fast.

The stability of vaccines and their packaging, according to the U.S. Centres for Disease Control and Prevention (CDC), is important since they affect the efficacy of the products, and careful controls need to be established to ensure they are difficult to approve. Moreover, the different laws of different countries make the task of manufacturers difficult in standardising the actual packaging of their product to be capable of distributing globally.

The World Health Organisation (WHO) highlights this regulatory fragmentation by indicating that variations in the regulatory frameworks are causing delays in making the vaccines available to different regions, hence limiting the growth of the market. All these difficulties add expenses and reduce the pace of new planning in packaging technology available in the world. Environmental requirements raise the question about the choice of packaging materials, also contributing to the increased complexity of the legislation since the manufacturers should perform the balancing between the eco-friendly measures and the law requirements. Because of this, companies have to spend a lot of funds to overcome these obstacles until large-scale use of vaccines is obtained in packaging.

Technological advancements enabling smart and sustainable packaging innovations.

The combination of intelligent markers and ecologically friendly materials is a tectonic shift in the packaging of vaccines, as it will naturally resolve existing problems with cold chains and minimise environmental pollution. More than 2 billion units (introduced in 1996) of VVMs (Vaccine Vial Monitors) have been deployed in immunisation programmes and have saved billions of vaccine doses under emergency and routine healthcare conditions. The high-stability VVMs may improve the safety of vaccine distribution in hot and remote locations, as they can maintain the potency of a vaccine for up to 30 days at high temperatures.

Plastic pre-filled syringes with advanced polymers have fewer needs for secondary packaging, with their physical wastes being reduced by about 50 per cent overall, a factor which facilitates logistics and enables the pursuit of sustainability objectives. Such advances conserve vaccine potency and limit wastage and the geographical extent of prevention programmes in lower-resource environments. Consequently, intelligent and eco-friendly packaging is becoming a promising area of investment and development in the field of vaccine supply chains. Further, digital technologies such as the use of QR code tracking and sensors fueled by IoT are increasing the supply chain transparency. Such innovations are gaining support on a global platform from governments and global health organisations in terms of funds and policy encouragement.

Expansion in emerging economies driving vaccination accessibility and need.

The high growth in the existing healthcare infrastructure of emerging economies is boosting vaccine accessibility significantly, which offers a massive scope to operate in the vaccine packaging market. Driven by the expansion of immunisation uptake by governments in parts of the world, including Asia, Africa, and Latin America, there will be continued pressure on the demand for highly functional, large-scale, and safe packaging material, including vials, cold chain systems, prefilled syringes, etc. In the view of the World Health Organisation (WHO), the world immunisation programmes have ballooned, with more than 80% of children worldwide accessing basic vaccines, of which the bulk has largely been given by the developing world. According to UNICEF in 2023, it placed more than 2.3 billion vaccine doses, most of which went to low- and middle-income countries.

The necessity of managing the efficacy of the vaccines and offering them quickly and effectively is further emphasised by national efforts like the India Universal Immunisation Programme and regional vaccine campaigns by the Africa CDC. Such momentum enhances the ability of the public health systems and drives the demand within the value chain of the vaccine packaging. The implementation of temperature-sensitive vaccines, such as mRNA COVID-19 vaccine doses, has further burdened the packaging technologies to be advanced. The need to increase the target populations to adult and booster vaccination adds even greater importance to the scalability and innovativeness of the packaging.

Segment Analysis

Based on the Packaging type, the Vaccine Packaging market has been classified into Vials, Ampoules, Prefilled Syringes, Cartridges, Bottles, and Others. Vials are the most outstanding and dominant combination of packaging in the market for vaccines. Their broad use is explained by the fact that they could be used with liquid and lyophilised (freeze-dried) vaccines, providing high protection, stabilisation, and matching with the cold chain supply. Vials can be produced cheaply in large quantities and can be stored in multiples. This is desirable when there is a large-scale immunisation exercise. Their longevity and convenience of sterilisation are the aspects through which they are the most preferred in both developed and developing healthcare environments. Such a high usage places the vials in the first position in terms of vaccine packaging.

Based on the Vaccine Type, the Vaccine Packaging market has been classified into Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, mRNA Vaccines, Viral Vector Vaccines, DNA Vaccines, and Others. mRNA vaccines have become the most important and leading division in the market of vaccine packaging in the past few years. The speed at which they were developed and deployed based on the COVID-19 pandemic has further fuelled the need to ensure the right kind of packaging, especially those that cater to the need to maintain a cold chain, which is ultra-cold since they are a mishap in making. This has promoted competition and spending on modern packaging solutions, and mRNA vaccines are at the top of the list of market expansion and market modification.

Regional Analysis

The intensive regional differences are evident in the United States vaccine packaging market due to the availability of the pharmaceutical centres, regulatory conditions, and the healthcare infrastructure. The Northeast area, especially the area around states such as Massachusetts and New Jersey, can be considered one of the major areas because of the high concentration of biotech and pharmaceutical companies that promote innovation in advanced packaging solutions. The West Coast includes California, which is also involved in focusing on research and development and startups focusing on new forms of vaccine delivery systems.

The Midwest has this advantage associated with powerful industries, including manufacturing, which can be used to pack vaccines in large quantities. Further, the Southern states are slowly taking their position as key participants due to ample investments in healthcare and cold supply networks. On the whole, the regional dynamics of the US vaccine packaging market can be described by the joint influence of technological innovations, the manufacturing capacity, and the proximity to the vaccine development hubs. Demand for sustainable and tamper-evident packaging is driving regional trends, and companies in these regions are following the trend of using environmentally friendly packaging to align themselves with the changing regulatory and consumer demands.

The Asia-Pacific region encompasses countries in East & Southeast Asia, Southern Asia, and Oceania, which are diverse and dynamic regions. It is characterised by a high economic growth rate, which comes through the leading economies such as China, Japan, India, and Australia. It is the core of international trade, technology, and manufacturing, and numerous nations are essential places of creation and creation. Asia Pacific is as rich and diverse culturally, with thousands of languages, traditions, and religions. The area struggles as well with the problems of the environment, political tensions, and social inequality. Nevertheless, despite these, Asia Pacific is still the core of defining respective economics, politics, and the culture of the globe in the 21st century.

Japan is among the world's top leaders in technology, economic strength, and power in international markets. Employment of innovation and sustainable growth among the people in Japan has enabled it to stay competitive in the use of innovative techniques and cultural diversity. Overall, Asia Pacific is a land of tradition and modernity, but it is still developing at a great pace. With the increasing degree of globalisation, there is a growing significance of the same about the cooperation of the region on economic and environmental aspects in sustaining stability and economic growth. This continuous cooperation is bound to determine the future of the Asia Pacific in the ensuing decades.

Competitive Landscape

The vaccine packaging market is quite competitive due to the growing global need for the delivery of safe and efficient solutions concerning vaccines. The market is dominated by such companies as Amcor plc, Gerresheimer AG, West Pharmaceutical Services, and Schott AG due to their wide portfolio of glass vials, plastic containers, and high-tech closures. The latest trend involves strategic alliances and capacities being developed to respond to the soaring demands in terms of the production of vaccines.

Gerresheimer and West Pharmaceutical Services have invested in new areas of manufacturing vials and sealing technology to promote the stability of vaccines. Companies such as AptarGroup and Catalent are preoccupied with the possibility of combining the technologies of advanced drug delivery and aseptic packaging to make the vaccines safer and distribute them more effectively. As the innovations continue and more focus on cold-chain packaging is made by companies such as CSafe, the industry has kept on evolving quickly with a focus on issues of reliability and scalability to meet the objective of global immunisation.

Vaccine Packaging Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Recent Developments:

• In May 2025, Schott Poonawalla, a joint venture between Schott Pharma and India’s Serum Institute, received investment from TPG. This funding helped the company expand its vaccine vial production and packaging capacity. The expansion supported Takeda’s rollout of the Qdenga dengue vaccine in India.
• In April 2025, UK researchers began human trials of SPVX02, a tetanus-diphtheria vaccine, using Stablepharma’s thermostable packaging technology. This fridge-free formulation was designed to stay stable at ambient temperatures ranging from –20 °C to 40 °C for up to 18 months.

Report Coverage:

By Packaging Type

• Vials
• Ampoules
• Prefilled Syringes
• Cartridges
• Bottles
• Others

By Vaccine Type

• Inactivated Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• mRNA Vaccines
• Viral Vector Vaccines
• DNA Vaccines
• Others

By Material

• Glass
• Plastics
• Rubber
• Aluminum Foil
• Paper & Paperboard
• Others

By Usage

• Single-Dose Packaging
• Multi-Dose Packaging

By Distribution Channel

• Direct Sales
• Distributors
• Online Channels
• Retail Pharmacies

By End User

• Hospitals & Clinics
• Vaccination Centers
• Pharmaceutical Companies
• Contract Manufacturing Organizations (CMOs)
• Government Agencies
• Research Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Amcor plc
• AptarGroup, Inc.
• Aseptic Technologies
• Berry Global, Inc.
• Catalent, Inc.
• Corning Incorporated
• CSafe Global
• DWK Life Sciences
• Fengchen Group
• Gerresheimer AG
• Nipro Corporation
• Schott AG
• SGD Pharma
• Stevanato Group
• West Pharmaceutical Services, Inc.

Frequently Asked Questions (FAQs)